OVID
$2.68
Ovid Therapeutics
($.01)
(.37%)
OVID
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.31)
Revenue:  $0.00 Mil
Thursday
Feb 11
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when OVID reports earnings?
Beat
Meet
Miss

Where is OVID's stock price going from here?
Up
Flat
Down
Stock chart of OVID
Analysts
Summary of analysts' recommendations for OVID
Score
Grade
Pivots
Resistance
$2.82
$2.76
$2.72

$2.66

Support
$2.62
$2.56
$2.52
Tweet
Growth
Description
Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States.